EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access

A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults

Carol M Kao, Christina A Rostad iD, Lauren E Nolan iD, Etza Peters, Jennifer Kleinhenz, Jacob D Sherman, Ashley Tippett, J Wai Kuo Shih, Inci Yildirim, Vivien Agbakoba, Tatiana Beresnev, Cassandra Ballou und 6 weitere

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae148 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Carol M Kao und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Hepatitis E, Immunoglobulin G. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Emory University School of Medicine, NIAID NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Establishing the safety and immunogenicity of a hepatitis E virus vaccine in multiple populations could facilitate broader access and prevent maternal and infant mortality.

Methods

We conducted a phase 1, randomized, double-blinded, placebo-controlled (4:1 vaccine to placebo) trial of 30 µg HEV-239 (Hecolin, Xiamen Innovax Biotech Company Limited, China) administered intramuscularly in healthy US adults aged 18–45 years. Participants were vaccinated on days 1, 29, and 180. Participants reported solicited local and systemic reactions for 7 days following vaccination and were followed through 12 months after enrollment for safety and immunogenicity (IgG, IgM).

Results

Solicited local and systemic reactions between treatment and placebo group were similar and overall mild. No participants experienced serious adverse events related to HEV-239. All participants receiving HEV-239 seroconverted at 1 month following the first dose and remained seropositive throughout the study. HEV-239 elicited a robust hepatitis E IgG response that peaked 1 month following the second dose (geometric mean concentration [GMC], 6.16; 95% confidence interval [CI], 4.40–8.63), was boosted with the third dose (GMC, 11.50; 95% CI, 7.90–16.75) and persisted through 6 months.

Conclusions

HEV-239 is safe and elicits a durable immune response through at least 6 months after the third dose in healthy US adults. Clinical Trials Registration NCT03827395.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis EImmunoglobulin GHumansAdultDouble-Blind MethodFemaleMaleYoung AdultUnited StatesMiddle AgedAdolescentViral Hepatitis VaccinesHepatitis E virusHepatitis AntibodiesImmunoglobulin MHealthy VolunteersImmunogenicity, VaccineInjections, IntramuscularVaccines, Synthetic

Stichwörter der Autor:innen

acute hepatitishepatitis Eimmunizationvaccinationviral hepatitis

Substanzen

hecolinImmunoglobulin GViral Hepatitis VaccinesHepatitis AntibodiesImmunoglobulin MVaccines, Synthetic

Autor:innen und Institutionen

  • Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Hope Clinic, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Xiamen Innovax Biotech Company Limited, Xiamen, China.
  • Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
  • The Emmes Company, LLC, Rockville, Maryland, USA.

ORCID-Profile: Christina A Rostad, Lauren E Nolan, Satoshi Kamidani, Nadine Rouphael

Förderung

  • Emory University School of Medicine
  • NIAID NIH HHS
  • NIH HHS
  • Children's Healthcare of Atlanta
  • National Institute of Allergy and Infectious Diseases
  • Georgia Research Alliance
  • National Institutes of Health
  • Children’s Healthcare of Atlanta

Zitieren

APA

Kao, C. M., Rostad, C. A., Nolan, L. E., Peters, E., Kleinhenz, J., Sherman, J. D., Tippett, A., Shih, J. W. K., Yildirim, I., Agbakoba, V., Beresnev, T., Ballou, C., Kamidani, S., Karmali, V., Natrajan, M., Scherer, E. M., Rouphael, N., & Anderson, E. J. (2024). A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae148

Vancouver

Kao CM, Rostad CA, Nolan LE, Peters E, Kleinhenz J, Sherman JD, et al. A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae148

BibTeX
@article{Kao2024,
  author = {Kao, Carol M and Rostad, Christina A and Nolan, Lauren E and Peters, Etza and Kleinhenz, Jennifer and Sherman, Jacob D and Tippett, Ashley and Shih, J Wai Kuo and Yildirim, Inci and Agbakoba, Vivien and Beresnev, Tatiana and Ballou, Cassandra and Kamidani, Satoshi and Karmali, Vinit and Natrajan, Muktha and Scherer, Erin M and Rouphael, Nadine and Anderson, Evan J},
  title = {A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae148}
}
Kostenlos starten →